Pulmonx (NASDAQ:LUNG) Price Target Lowered to $16.00 at Stifel Nicolaus

Pulmonx (NASDAQ:LUNG) had its target price trimmed by Stifel Nicolaus from $17.00 to $16.00 in a research report released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also issued reports on the company. Wells Fargo & Company decreased their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Canaccord Genuity Group upped their target price on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.67.

Pulmonx Trading Up 0.3 %

Shares of NASDAQ LUNG opened at $6.27 on Thursday. The business’s 50 day moving average is $7.24 and its two-hundred day moving average is $7.25. Pulmonx has a 52-week low of $5.46 and a 52-week high of $14.84. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 51.92%. The company had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. During the same period in the prior year, the firm earned ($0.39) earnings per share. As a group, equities research analysts predict that Pulmonx will post -1.64 EPS for the current fiscal year.

Insider Buying and Selling at Pulmonx

In other news, CEO Steven S. Williamson acquired 14,245 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were bought at an average price of $6.84 per share, with a total value of $97,435.80. Following the completion of the acquisition, the chief executive officer now owns 219,531 shares in the company, valued at $1,501,592.04. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Steven S. Williamson purchased 14,245 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were bought at an average price of $6.84 per share, with a total value of $97,435.80. Following the completion of the transaction, the chief executive officer now directly owns 219,531 shares in the company, valued at approximately $1,501,592.04. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total value of $130,400.00. Following the transaction, the director now directly owns 1,091,974 shares in the company, valued at approximately $7,119,670.48. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,351 shares of company stock worth $361,494 over the last three months. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in Pulmonx during the third quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Pulmonx in the second quarter valued at approximately $37,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Pulmonx by 609.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock valued at $79,000 after purchasing an additional 7,316 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Pulmonx in the first quarter valued at approximately $102,000. Finally, SG Americas Securities LLC acquired a new position in shares of Pulmonx in the third quarter valued at approximately $102,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.